ADA session notes
ADA session notes
The following are points of interest from the American Diabetes Association Scientific Sessions in San Diego in June:
• After a workshop conducted by the ADA’s Council on Behavioral Medicine and Psychology, representatives from the ADA, National Institutes of Health, and Nurses Research Institute say now is the time to ask for grant money to fund behavioral research in diabetes management. Council president Daniel J. Cox, PhD, noted the council would try to help sharpen the research skills of behavioral therapists to encourage more of them to do more research and report their findings. He noted a place to start is through communicating with the council through e-mail. Links are available through the council, which can be found on the ADA Web site at www.diabetes.org.
• Reducing diabetes-related heart disease is as simple as taking an aspirin a day, but fewer than one in five American diabetics are doing so. While 98% of all diabetics are eligible to take the ADA-recommended dosage of 81 mg to 325 mg of enteric-coated aspirin, according to Centers for Disease Control and Prevention statistics, only 37% of the patients with diagnosed cardiovascular disease and 13% of those with cardiovascular disease risk reported regular aspirin use in the NHANESIII (National Health and Nutrition Examination Survey).
• Diabetic patients have a significantly increased mortality six months after a myocardial infarction, Scottish researchers reported. Christopher J.G. Kelly, MD, of Stobhill Hospital in Glasgow, Scotland, found that six-month post MI all-cause mortality in the diabetic group was 33% in the diabetic group and 13% in the non-diabetic group. Kelly suggests that diabetics present to emergency rooms later due to atypical symptoms and upon arrival are at risk of receiving inappropriate thrombosis and/or secondary prevention.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.